Passive immunization as tool to identify protective HIV-1 Env epitopes.

Area of Science:

• Immunology
• Vaccinology
• Virology

Background:

• The global HIV-1/AIDS epidemic persists with no broadly protective vaccine available.
• Early vaccine candidates like gp120 failed to elicit broadly neutralizing antibodies (nAbs) or provide protection in clinical trials.
• Renewed interest in nAbs emerged following successful passive immunization studies in non-human primates.

Purpose of the Study:

• To evaluate the protective potential of neutralizing antibodies (nAbs) against HIV-1.
• To identify conserved epitopes targeted by protective nAbs.
• To assess the feasibility of developing active immunization strategies based on identified epitopes.

Main Methods:

• Passive immunization of macaques with human neutralizing monoclonal antibodies (nmAbs) against simian-human immunodeficiency viruses (SHIVs).
• Analysis of nmAbs targeting conserved epitopes on HIV-1 envelope glycoproteins (gp120 and gp41).
• Structural elucidation of protective epitopes and assessment of nmAbs for autoreactivity.

Main Results:

• Passive immunization with specific nmAbs conferred complete protection against SHIV challenge in macaques.
• Protective nmAbs targeted conserved, functionally critical epitopes on gp120 and gp41.
• Some protective nmAbs exhibited autoreactivity, posing challenges for active immunization induction of B-cell responses.

Conclusions:

• Passive immunization is a valuable tool for identifying correlates of protective immunity and potential vaccine targets.
• Dissociating broad neutralization from autoreactivity is crucial for designing effective active immunization strategies.
• Further research is needed to identify non-autoreactive epitopes and evaluate antibodies against non-clade B HIV-1 strains.